|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. David Loew||MD, CEO & Director||2,22M||S.O.||1967|
|Mr. Aymeric Le Chatelier||Executive VP & Group CFO||731,25k||S.O.||1969|
|Dr. Aidan Murphy Ph.D.||Executive Vice President of Technical Operations||S.O.||S.O.||1966|
|Mr. Craig Marks||Vice-President of Investor Relations||S.O.||S.O.||S.O.|
|Mr. Francois Garnier||Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer||S.O.||S.O.||1962|
|Ms. Gwenan White||Executive Vice President of Communications, Public Affairs & Sustainability||S.O.||S.O.||S.O.|
|Mr. Regis Mulot||Executive VP & Chief Human Resources Officer||S.O.||S.O.||1966|
|Ms. Dominique Bery||Head of Nordics & Baltics||S.O.||S.O.||1971|
|Mr. Bartosz Bednarz D.D.S.||Executive VP and Head of Global Product & Portfolio Strategy||S.O.||S.O.||S.O.|
|Mr. Philippe Lopes-Fernandes CBO||Executive VP & Chief Business Officer||S.O.||S.O.||S.O.|
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
L’ISS Governance QualityScore de Ipsen S.A. en date du 28 novembre 2023 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 7; Compensation : 6.